Kura Oncology
KURA
220 hedge funds and large institutions have $953M invested in Kura Oncology in 2026 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 91 increasing their positions, 65 reducing their positions, and 25 closing their positions.
470% more call options, than puts
Call options by funds: $5.46M | Put options by funds: $959K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 65
39% more capital invested
Capital invested by funds: $686M → $953M (+$267M)
12% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 25
2.36% more ownership
Funds ownership: 95.58% → 97.94% (+2.4%)
1% less funds holding
Funds holding: 222 → 220 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$13.3M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$9.46M |
| 3 |
BlackRock
New York
|
+$8.22M |
| 4 |
Goldman Sachs
New York
|
+$7.85M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$12.6M |
| 2 |
Millennium Management
New York
|
-$8.06M |
| 3 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$7.56M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.27M |
| 5 |
Jane Street
New York
|
-$5.56M |
KURA Hedge Fund Activity: Q2 2026 in Review
220 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2026, worth a combined $953M — up 39% from $686M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new KURA positions and 25 closed out — a net gain of 3 holders — while 91 added to existing stakes and 65 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $13.3M. The largest seller was Prosight Management, cutting an estimated $12.6M.
- 220 institutional investors held Kura Oncology (KURA) as of Q2 2026, down from 222 in Q1 2026.
- Funds reported $953M of Kura Oncology stock for Q2 2026, up 39% quarter-over-quarter.
- 28 funds opened new Kura Oncology positions in Q2 2026 and 25 closed out, a net change of +3 holders.
- The largest Kura Oncology buyer in Q2 2026 was Arrowstreet Capital, an estimated $13.3M added.
- The largest Kura Oncology seller in Q2 2026 was Prosight Management, an estimated $12.6M sold.
Based on aggregated 13F filings for Q2 2026.